Gene therapy offers hope for rare blindness
NCT ID NCT06196827
First seen Mar 16, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early-stage study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes vision loss. The treatment uses a harmless virus to deliver a working copy of the RPE65 gene to the retina. The main goals are to check safety and see if it can improve vision in 9 participants aged 6 and older.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China
-
Shanghai General Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.